For investors looking for high-growth chances, a mixed method that examines both fundamental momentum and technical condition can be an effective plan. This process finds companies with strong, quickening earnings and sales growth—a sign of the high-growth momentum style—while also finding those whose stock charts are forming into possible breakout shapes. By selecting for stocks with a good High Growth Momentum Rating, a firm Technical Rating, and a high Setup Quality Rating, investors try to find companies where strong business results match a technically favorable entry point. PTC THERAPEUTICS INC (NASDAQ:PTCT) appears from such a filter, offering a case study in this two-part method.
High Growth Momentum Fundamentals
The center of the high-growth momentum plan is to find companies with outstanding and often quickening business results. PTC Therapeutics displays several important traits that build its firm High Growth Momentum Rating of 6.
- Outstanding Earnings Growth: The company's trailing twelve-month (TTM) EPS growth is at a notable 277%. More lately, the last reported quarter showed a year-over-year EPS growth of 114%, after a remarkable 936.7% growth in the quarter before. This shows important short-term earnings momentum.
- Firm Cash Flow Generation: Free cash flow, a vital measure of financial health and quality of earnings, has risen by about 376% over the past year. This shows the company's growth is turning into real cash, not just accounting profits.
- Positive Analyst Revisions: Analyst sentiment is a key forward-looking signal. Over the last three months, the average estimate for next year's EPS has been moved upward by over 30%, hinting at increasing confidence in the company's near-term profit path.
- Earnings Surprises: The company has exceeded EPS estimates in three of the last four quarters, with an average beat of over 1,100%. Steady positive surprises can be a sign of management performance beating expectations.
While sales growth in the most recent quarter was more moderate at 7.2%, it comes after a quarter of large 459.7% growth. The mix of strong earnings increase, rising cash flow, and positive estimate revisions forms a notable fundamental picture for momentum investors centered on quickening financial performance.
Technical Condition and Trend
A strong fundamental story must be backed by a healthy price trend to draw momentum capital. According to the ChartMill Technical Analysis report, PTCT gets a Technical Rating of 7, signaling a stock in a confirmed uptrend with clear relative strength.
- Long-Term Uptrend Holding: The long-term trend is graded as positive, with the stock trading well above its rising 100-day and 200-day simple moving averages. This gives a favorable setting for continuation moves.
- Market Beating Performance: Over the past year, PTCT has done better than 90% of all stocks in the market, a clear mark of institutional support and leadership. It also does better than 77% of its peers in the competitive Biotechnology industry.
- Sturdy Performance: The report states that the gains over the past year have been "nicely spread over this period," hinting at a steady climb rather than a single, unstable spike.
This technical rating confirms that the stock is behaving well from a price view, matching the positive fundamental story. A stock can have excellent fundamentals but struggle if it lacks technical condition; PTCT seems to have both.
A High-Quality Setup Pattern
Maybe the most notable part for a tactical investor is the present chart pattern. PTCT has a Setup Quality Rating of 8, which finds stocks forming in a tight band after a rise, often before a new breakout.
- Formation Within a Band: The technical report states the stock has been trading between $69.81 and $80.18 over the past month and is now in the middle of this band. This time of lower volatility and sideways movement lets the stock absorb its prior gains and build a new base of support.
- Clear Support and Resistance: The analysis finds a firm support area between $72.48 and $75.18, made by a mix of moving averages and trendlines. Close overhead resistance is noted at $78.90. These set levels help in planning exact trade entries and risk management.
- Automated Trade Idea: Based on this setup, the report describes a possible trading situation. It proposes an entry on a breakout above the $78.90 resistance level, with a stop-loss set below the support area near $72.47. This sets the trade's risk at about 8.2% from entry to stop.
This high setup rating is key because it deals with the "when" to buy. It hints the stock is not stretched but is instead forming in a consolidation, possibly giving a lower-risk entry point if it continues its upward trend.
Finding Like Chances
The method that highlighted PTC Therapeutics, mixing high growth momentum, technical condition, and a quality setup, can be used in a regular way to find other possible chances in the market. This disciplined filter helps sort thousands of stocks down to a focused list where notable fundamentals and promising technicals meet.
For investors wanting to see the present list of stocks that fit these exact rules, you can view the live results of this filter here: High Growth Momentum Breakout Setups.
Disclaimer: This article is for information only and does not make up investment advice, a suggestion, or an offer or request to buy or sell any securities. The study given is based on data and tools from ChartMill and should not be the only base for any investment choice. All investing includes risk, including the possible loss of principal. Past performance is not a sign of future results. Always do your own research and think about talking with a qualified financial advisor before making any investment choices. The automated trade setup noted is an example for learning and is not a promise of future performance.